SRZN Surrozen, Inc. Common
XNAS
33.65
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
SRZN
$33.65
—
What changed
Recent filings, trades and movesKey stats
$33.65
- 52-Week Range
- $11.73 – $37.83
- YTD
- +56.15%
- IV Rank (30D)
- 0.0
- Straddle Price
- $7.00
- P/C Vol Ratio
- 2.41
- Market Cap
- $0.4B
- Open
- $33.43
- Day Range
- $32.76 – $33.75
- Volume
- 11,762
- Prev Close
- $32.64
Fair Value
-50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.84% |
| Beta vs SPY | 0.69 |
| Cost of Equity (CAPM) | 8.31% (VRP-adj) |
| WACC | 8.46% |
| Volatility Risk Premium | +21.3pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | 160.2% |
| Book / Price | -59.9% |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $25.14 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $27.49 |
| Bollinger Width / SMA20 | 41.5% (drives anchor stability) |
| Net Debt | $0.0B |
| Market Cap | $0B |
Peers used for multiples: CON, CYTK, EXEL, HALO, NBIX, PGNY, PTCT, VCEL
Blended Fair Value
$6.00
Deviation
-50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 26.4× · 6 peers |
| Peer EV/EBITDA | n/a | 0% | median 16.2× · 7 peers |
| Peer P/B | n/a | 0% | median 8.3× · 6 peers |
| Peer P/S | $6.00 | 100% | median 5.8× · 8 peers |
| Market Anchor (SMA50) | $25.14 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $31.43 | 0% | 7 strikes · skew +0.12 |
As of 2026-11-10 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.4B
- Employees
- 44
- List Date
- 2021-08-12
- CIK
- 0001824893
- Last Earnings
- Nov 9 · +2.0% vs ±22.2% expected
- Headquarters
- South San Francisco, CA
- Homepage
- https://www.surrozen.com
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -60.23% | 25.99% | -22.17% | -18.60% | -0.02% | -15.01% |
| Feb | -- | 29.61% | 41.12% | 57.58% | 5.09% | 25.79% | 31.84% |
| Mar | -- | -3.22% | -46.73% | 18.57% | 8.97% | 1.85% | -4.11% |
| Apr | -- | -10.45% | 1.67% | 6.53% | -0.99% | 17.44% | 2.84% |
| May | -- | -4.98% | -0.03% | 13.35% | -18.99% | -21.99% | -6.53% |
| Jun | -- | 17.65% | -6.46% | -4.03% | 9.96% | 5.02% | 4.43% |
| Jul | -- | -19.05% | 26.35% | -24.67% | 13.51% | -12.90% | -3.35% |
| Aug | -24.10% | -14.33% | -34.64% | 31.66% | 10.77% | 1.10% | -4.92% |
| Sep | -7.15% | -26.01% | -11.23% | 12.81% | 4.59% | 44.95% | 2.99% |
| Oct | -1.96% | 12.94% | -21.22% | 22.07% | 2.49% | -3.20% | 1.85% |
| Nov | 18.72% | -72.60% | 17.65% | -7.79% | 26.95% | 12.47%* | -0.77% |
| Dec | -26.48% | 5.78% | 27.89% | 26.21% | 40.20% | -- | 14.72% |
| Total | -39.69% | -91.61% | -21.75% | 167.86% | 97.22% | 71.26% | 30.55% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $28.42
SMA 50: $25.57
SMA 200: $25.54
Current: $33.31
EMA 12: $30.51
EMA 26: $28.64
MACD: 1.8666 | Signal: 0.3916
BULLISH
ADX (14): 35.09
TREND
+DI: 32.41
−DI: 13.40
Momentum Oscillators
RSI (14): 64.60
NEUTRAL
Stoch %K: 89.21
Stoch %D: 82.80
Williams %R: -4.79
Volume & Volatility
BB Upper: $34.36
BB Lower: $22.49
NEUTRAL
OBV: 13,975,901
Vol SMA 20: 291,755
Vol ROC: -92.05%
ATR: $2.38
True Range: $1.11
HV 20: 68.9%
HV 30: 97.7%
HV 60: 173.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-12T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Written before SRZN’s Nov 9 earnings report, so it doesn’t reflect the results.
Here is the LLM Stock Analysis Prompt Template filled with an analysis of the stock SRZN:
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers: Trend direction, momentum signals, and recent news sentiment impact.
Primary Risks: Volatility regime, options market signals, and earnings catalysts.
Investment Thesis: SRZN's technical indicators suggest a neutral stance, with mixed signals from trend direction, momentum oscillators, and Bollinger Bands. Recent news headlines are not available, but the stock's low volatility and stable beta make it an attractive option for conservative investors. However, further analysis is needed to determine if this stability is sustainable or if a potential breakout/breakdown is imminent.
Recent News Sentiment Impact: N/A (No recent news available)
Technical Analysis
Trend Direction:
- Short-term: NEUTRAL
- Medium-term: BEARISH
- Long-term: BULLISH
Support/Resistance Levels:
- SMA 20: $20.56 (support)
- EMA 12: $21.77 (resistance)
- Upper Bollinger Band: $26.39 (resistance)
Momentum Signals:
- RSI (14): 66.08 (neutral)
- MACD: Bullish signal
- Stochastic %K: 76.12
- Stochastic %D: 74.45
Volume Analysis:
- Volume SMA 20: 114872.55
- On-Balance Volume (OBV): 2016367.00
- Volume Rate of Change: -94.06% (indicating a decrease in volume)
News & Sentiment Analysis
Recent Headlines Summary: N/A (No recent news available)
Sentiment Assessment: NEUTRAL
Catalyst Identification: Earnings catalysts, regulatory changes, and product launches
Market Narrative: The lack of recent news headlines makes it challenging to determine the market narrative. However, SRZN's stable beta and low volatility suggest that the stock is likely to continue trading within a narrow range.
Risk & Volatility Assessment
Beta Interpretation: Low risk (beta = 0.67)
Volatility Regime: Low volatility
Options Market Signals: N/A (No options data available)
Downside Protection:
- Support levels: SMA 20 ($20.56)
- Risk management considerations: Conservative investors may want to consider stop-loss levels near the support level.
Market Context & Positioning
Sector Performance: N/A (No sector performance data available)
Institutional Activity: Low institutional interest
Correlation Analysis: SRZN's low volatility and stable beta indicate a low correlation with market movements.
Relative Valuation: SRZN is trading within its historical range, indicating that it may not be overvalued or undervalued at this time.
Key Levels & Action Items
Critical Price Levels:
- Support level: SMA 20 ($20.56)
- Resistance level: EMA 12 ($21.77)
Breakout/Breakdown Levels: N/A (No breakout/breakdown levels identified)
Time-Sensitive Catalysts: Upcoming earnings date, product launch
Risk Management:
- Stop-loss levels: near the support level
- Position sizing considerations: Conservative investors may want to consider reducing their position size due to SRZN's low volatility.
Please let me know if this meets your expectations or if you need any further assistance!
Generated
News
All SRZN news →
Earnings History
1 of 1 under expected move
Avg Expected Move
22.19%
Avg Actual Move
2.00%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2026-11-09 | unknown | 22.19% | 2.00% | 0.09x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
SRZN Options Activity & IV Rank
SRZN IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 79.6%
7-DTE IV: 99.4%
Expected Move: $7.00
7-DTE Move: $4.53
Days to Exp: 37 (2026-12-18)
Options Flow · All expiries
Call Volume: 109
Put Volume: 263
P/C Volume: 2.413
BEARISH
Call OI: 185
Put OI: 542
P/C OI: 2.93
Total OI: 727
ATM Options Pricing
ATM Call: $2.35
ATM Put: $4.65
Call %: 7.0%
Put %: 13.8%
Chain Summary
Chain Volume: 372
Chain OI: 727
Last Updated: 11/11/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 87th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
87%
vs own history
GEX tilt
+0.37
OI-weighted, today
Vanna tilt
+0.87
δ-sensitivity to IV
Charm tilt
-0.98
δ-decay vs time
Vanna tilt +0.87: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.98: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 4 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)0.0LowNov 11
Straddle Price (30 DTE)$7.00Nov 11
Beta Analysis
Risk Metrics
Beta: 1.5920
Alpha: 153.65%
Correlation: 0.1601
R-Squared: 2.6%
Stock Volatility: 135.9%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own SRZN
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $17.7M | #1195 of 3716 | -6.6% | 13F | |
| Point72 Hedge fund Steve Cohen | $17.2M | #623 of 1945 | new | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $321K | #2752 of 3138 | -74.8% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
SRZN Institutional Ownership (13F)
Filings for 2026-06-30 · 16 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
2 filers$84.89K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Simplex Trading, LLC Custodian | $83.67K | 98.56% | 2026-09-30 |
| 2 | Millennium Management LLC Custodian | $1.22K | 1.44% | 2026-06-30 |
1 filers$154.46K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Simplex Trading, LLC Custodian | $154.46K | 100.00% | 2026-09-30 |
SRZN Insider Trading (Form 4)
Latest: 2026-10-22Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-22 | Tim Kutzkey | Director | Exer (X) | +1,551,724 | $11.60 | $18.00M | EDGAR |
| 2026-10-22 | Column Group Opportunity III GP, LP | 10%+ Owner | Exer (X) | +1,551,724 | $11.60 | $18.00M | EDGAR |
| 2026-07-24 | TCG Crossover GP II, LLC | 10%+ Owner | Sell (S) | −325,000 | $21.25 | -$6.91M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
SRZN Insider Holdings
3 insiders · @ $33.31
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Tim Kutzkey | Director | 1,565,311 | $52.14M | $0 | 1 | 2026-10-22 |
| 2 | Column Group Opportunity III GP, LP | 10%+ Owner | 1,565,311 | $52.14M | $0 | 1 | 2026-10-22 |
| 3 | TCG Crossover GP II, LLC | 10%+ Owner | 574,047 | $19.12M | -$6.91M | 1 | 2026-07-24 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
SRZN Board & Officers
As of SEC filings through Oct 22, 2026Directors 6
- Anna Berkenblit · since Aug 11, 2021
- Christopher Y Chai · since Aug 11, 2021
- Craig C Parker · since Aug 11, 2021
- David J Woodhouse · since Aug 11, 2021
- Mace Rothenberg · since Aug 11, 2021
- Mary Haak-Frendscho · since Aug 11, 2021
Officers 4
- Craig C Parker · Chief Executive Officer · since Aug 11, 2021
- Yang Li · Exec. Vice President, Research · since Aug 17, 2023
- Andrew Pedrum Maleki · Chief Financial Officer · since Nov 12, 2025
- Charles O Williams · Chief Operating Officer · listed since Dec 2025
10% owners 8
- Column Group III Gp, LP (entity) · since Aug 11, 2021
- Column Group III, LP (entity) · since Aug 11, 2021
- Column Group Iii-A, LP (entity) · since Aug 11, 2021
- Column Group Opportunity III GP, LP (entity) · on file since Mar 2025
- Column Group Opportunity III, LP (entity) · on file since Mar 2025
- Peter Svennilson · on file since Jan 2026
- TCG Opportunity III GP, LLC (entity) · on file since Mar 2025
- Tim Kutzkey · listed since Dec 2025
Changes in the last 10 years (73)
| Jul 24, 2026 | TCG Crossover GP III, LLC reported in an SEC filing no longer being a 10% owner |
| Jul 24, 2026 | TCG Crossover GP II, LLC reported in an SEC filing no longer being a 10% owner |
| Jul 24, 2026 | TCG Crossover Fund III, L.P. reported in an SEC filing no longer being a 10% owner |
| Jul 24, 2026 | TCG Crossover Fund II, L.P. reported in an SEC filing no longer being a 10% owner |
| Jan 26, 2026 | The company announced the departure of Shao-Lee Lin from the board in an SEC filing |
| Jan 26, 2026 | TCG Crossover GP III, LLC became a 10% owner |
| Jan 26, 2026 | TCG Crossover GP II, LLC became a 10% owner |
| Jan 26, 2026 | TCG Crossover Fund III, L.P. became a 10% owner |
| Jan 26, 2026 | TCG Crossover Fund II, L.P. became a 10% owner |
| Jan 8, 2026 | Peter Svennilson first on file as a 10% owner |
| Dec 16, 2025 | Charles O Williams listed as Chief Operating Officer (previously CFO and COO) in SEC filings |
| Dec 2, 2025 | Tim Kutzkey first listed as a 10% owner in an SEC filing |
| Nov 12, 2025 | Andrew Pedrum Maleki became Chief Financial Officer |
| Mar 28, 2025 | Tim Kutzkey no longer listed as a 10% owner in SEC filings |
| Mar 28, 2025 | TCG Opportunity III GP, LLC first on file as a 10% owner |
| Mar 28, 2025 | Column Group Opportunity III, LP first on file as a 10% owner |
| Mar 28, 2025 | Column Group Opportunity III GP, LP first on file as a 10% owner |
| Jun 30, 2024 | The company announced the departure of Tim Kutzkey from the board in an SEC filing |
| Apr 8, 2024 | Charles O Williams listed as CFO and COO (previously Chief Financial Officer) in SEC filings |
| Aug 17, 2023 | Yang Li became Exec. Vice President, Research |
| Jul 14, 2023 | The company announced the departure of Wen-Chen Yeh as Chief Scientific Officer in an SEC filing |
| Apr 5, 2023 | The company announced the departure of Eric Bjerkholt from the board in an SEC filing |
| Apr 5, 2023 | Eric Bjerkholt became a director |
| Dec 15, 2022 | Mitchell J Md Blutt reported in an SEC filing no longer being a director |
| Dec 15, 2022 | Mitchell J Md Blutt reported in an SEC filing no longer being a 10% owner |
| Dec 15, 2022 | Consonance Capman GP, LLC reported in an SEC filing no longer being a director |
| Dec 15, 2022 | Consonance Capman GP, LLC reported in an SEC filing no longer being a 10% owner |
| Dec 15, 2022 | Consonance Capital Management LP reported in an SEC filing no longer being a director |
| Dec 15, 2022 | Consonance Capital Management LP reported in an SEC filing no longer being a 10% owner |
| Dec 15, 2022 | Benny Soffer reported in an SEC filing no longer being a director |
| Aug 13, 2021 | Mitchell J Md Blutt first listed as a 10% owner in an SEC filing |
| Aug 13, 2021 | Life Sciences Consonance reported in an SEC filing no longer being a director |
| Aug 13, 2021 | Life Sciences Consonance reported in an SEC filing no longer being a 10% owner |
| Aug 13, 2021 | Kevin Harold Livingston reported in an SEC filing no longer being Chief Financial Officer |
| Aug 13, 2021 | Jennifer Jarrett reported in an SEC filing no longer being a director |
| Aug 13, 2021 | Donald J Santel reported in an SEC filing no longer being a director |
| Aug 13, 2021 | Christopher Haqq reported in an SEC filing no longer being a director |
| Aug 11, 2021 | Wen-Chen Yeh became Chief Scientific Officer |
| Aug 11, 2021 | Tim Kutzkey became a director |
| Aug 11, 2021 | Tim Kutzkey became a 10% owner |
| Aug 11, 2021 | Shao-Lee Lin became a director |
| Aug 11, 2021 | Mary Haak-Frendscho became a director |
| Aug 11, 2021 | Mace Rothenberg became a director |
| Aug 11, 2021 | Joshua Cory House left as VP Business Development, per their own SEC filing |
| Aug 11, 2021 | Geertrui Vanhove became Chief Medical Officer |
| Aug 11, 2021 | Gad Soffer left the board, per their own SEC filing |
| Aug 11, 2021 | David J Woodhouse became a director |
| Aug 11, 2021 | Craig C Parker became a director |
| Aug 11, 2021 | Craig C Parker became Chief Executive Officer |
| Aug 11, 2021 | Column Group Iii-A, LP became a 10% owner |
| Aug 11, 2021 | Column Group III, LP became a 10% owner |
| Aug 11, 2021 | Column Group III Gp, LP became a 10% owner |
| Aug 11, 2021 | Christopher Y Chai became a director |
| Aug 11, 2021 | Charles O Williams became Chief Financial Officer |
| Aug 11, 2021 | Anna Berkenblit became a director |
| May 19, 2021 | Mitchell J Md Blutt no longer listed as a 10% owner in SEC filings |
| May 19, 2021 | Life Sciences Consonance first listed as a director in an SEC filing |
| Dec 4, 2020 | Mitchell J Md Blutt first listed as a 10% owner in an SEC filing |
| Dec 4, 2020 | Consonance Capman GP, LLC first on file as a 10% owner |
| Dec 4, 2020 | Consonance Capital Opportunity Fund Management LP first on file as a 10% owner |
| Dec 4, 2020 | Consonance Capital Management LP first on file as a 10% owner |
| Nov 18, 2020 | Mitchell J Md Blutt became a director |
| Nov 18, 2020 | Life Sciences Consonance became a 10% owner |
| Nov 18, 2020 | Kevin Harold Livingston became Chief Financial Officer |
| Nov 18, 2020 | Joshua Cory House became VP Business Development |
| Nov 18, 2020 | Jennifer Jarrett became a director |
| Nov 18, 2020 | Gad Soffer became a director |
| Nov 18, 2020 | Donald J Santel became a director |
| Nov 18, 2020 | Consonance Capman GP, LLC became a director |
| Nov 18, 2020 | Consonance Capital Opportunity Fund Management LP became a director |
| Nov 18, 2020 | Consonance Capital Management LP became a director |
| Nov 18, 2020 | Christopher Haqq became a director |
| Nov 18, 2020 | Benny Soffer became a director |
Not reported recently (2)
- Geertrui Vanhove · Last reported as Chief Medical Officer in an SEC filing dated Dec 19, 2022
- Consonance Capital Opportunity Fund Management LP · Last reported as a director in an SEC filing dated Dec 4, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-11-09
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
16 ETFs hold SRZN
16 shown · $27.92M total exposure · 0.02% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $9.1M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $5.9M | $77.9B | 2026-11-06 |
| 3 | JSMD Janus Henderson Small/Mid Cap Growth Alpha ETF | Janus | 0.53% | $5.3M | $1.0B | 2026-11-06 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $2.6M | — | 2026-09-30 |
| 5 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.02% | $2.2M | $14.2B | 2026-11-06 |
| 6 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $1.4M | — | 2026-09-30 |
| 7 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.06% | $702,088 | $1.2B | 2026-11-06 |
| 8 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.04% | $404,488 | $1.0B | 2026-11-06 |
| 9 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.02% | $256,571 | — | 2026-09-30 |
| 10 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $114,144 | — | 2026-11-09 |
| 11 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $21,078 | — | 2026-09-30 |
| 12 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.01% | $13,248 | — | 2026-11-09 |
| 13 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $10,176 | — | 2026-11-09 |
| 14 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $7,104 | — | 2026-11-09 |
| 15 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $288 | — | 2026-11-09 |
| 16 | RB ProShares Russell 2000 Dynamic Buffer ETF | ProShares | 0.01% | $96 | — | 2026-11-09 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
-1.72
P/S
32.67
EV/EBITDA
-6.21
EV/Sales
23.81
ROE
160.2%
ROA
-303.0%
Div Yield
0.00%
FCF Yield
-9.30%
Debt/Equity
-0.00
Current Ratio
12.14
Market Cap
$376.11M
as of 2026-11-09
SRZN vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| EXEL Exelixis Inc | $17.5B | 21.0 | +9.1% | +61.3% | 23 |
| NBIX Neurocrine Biosciences Inc | $17.1B | 25.0 | +38.0% | +19.8% | 27 |
| HALO Halozyme Therapeutics, Inc. | $11.7B | 29.1 | +41.2% | +41.9% | 46 |
| CYTK Cytokinetics Inc. | $7.7B | — | −21.1% | −8.7% | 63 |
| PTCT PTC Therapeutics, Inc. | $5.4B | — | −35.1% | −16.4% | 23 |
| CON Concentra Group Holdings Parent, Inc. | $5.4B | 27.6 | +14.0% | +120.2% | 28 |
| VCEL Vericel Corporation | $3.0B | 98.8 | +25.3% | +66.4% | 8 |
| PGNY Progyny, Inc. Common Stock | $2.6B | 33.4 | +5.5% | +41.6% | 2 |
| SRZN Surrozen, Inc. Common | $376M | — | — | +54.6% | 0 |
| Peer median | $6.6B | 28.4 | +11.6% | +41.8% | 25 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
3.13M
SI % of Float
37.03%
Days to Cover
4.77
Short Vol Ratio
71.3%
Free Float
8.46M
Float %
72.0%
Short interest 2026-10-15 • Short volume 2026-11-10 • Float 2026-10-01